Local epigenetic reprograming induced by G-quadruplex ligands by Balasubramanian, Shankar
	   1	  
Local epigenetic reprograming  
 induced by G-quadruplex ligands  
 
Guillaume Guilbaud1,§, Pierre Murat2,3,§, Bénédicte Recolin1, Beth C. 
Campbell2, Ahmed Maiter1, Julian E. Sale1,* & Shankar Balasubramanian 2,3,4,* 
 
1 MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, 
CB2 0QH, UK  
 
2 Department of Chemistry, University of Cambridge, Lensfield Road, 
Cambridge CB2 1EW, UK. 
 
3 Cancer Research UK Cambridge Institute, University of Cambridge, Li 
Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK. 
 
4 School of Clinical Medicine, University of Cambridge, Cambridge CB2 
0SP, UK. 
 
* Correspondence to: Julian Sale (jes@mrc-lmb.cam.ac.uk) or Shankar 
Balasubramanian (sb10031@cam.ac.uk) 
 
§ These authors have contributed equally to this work. 
 
 
DNA and histone modifications regulate transcriptional activity and thus 
represent valuable targets to reprogram the activity of genes. Current 
epigenetic therapies target the machinery that regulates these 
modifications, leading to global transcriptional reprogramming with the 
potential for extensive undesired effects. Epigenetic information can 
also be modified as a consequence of disrupting processive DNA 
replication. Here we demonstrate that impeding replication by small 
molecule-mediated stabilisation of G-quadruplex nucleic acid 
secondary structures triggers local epigenetic plasticity. We report the 
use of the BU-1 locus of chicken DT40 cells to screen for small 
molecules able to induce G-quadruplex-dependent transcriptional 
reprogramming. Further characterisation of the top hit compound 
revealed its ability to induce a dose-dependent inactivation of BU-1 
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expression in two steps, first loss of H3K4me3 and subsequently DNA 
cytosine methylation, changes that were heritable across cell divisions 
even after the compound was removed. Targeting DNA secondary 
structures thus represents a potentially new approach for locus-specific 
epigenetic reprogramming. 
 
The ability to manipulate transcriptional activity in vivo has the potential to 
modify the development and progression of diverse pathological states. In 
particular, many cancers exhibit substantial dysregulation of gene expression 
associated with global changes in DNA methylation and histone modifications 
1. There has been much recent interest in ‘epigenetic’ therapies that target 
histone methyl transferases, demethylases and deacetylases, which are 
commonly dysregulated in cancer cells. For instance, histone deacetylase 
inhibitors, such as Vorinostat or Phenylbutyrate, and DNA methyltransferase 
inhibitors, such as 5-Aza-CR (azacitidine), have proven useful for treating 
haematological malignancies and are currently in clinical use 2.  
 
In vertebrate cells, it is becoming clear that the faithful transmission of 
epigenetic information, encoded in histone and DNA modifications, through 
DNA replication is important for the maintenance of gene expression patterns 
3,4. Preservation of this information relies on the coupling of DNA synthesis 
with transfer of modified histones from the parental to the nascent daughter 
DNA strands, a process that requires an intricate, but as yet incompletely 
understood, network of histone chaperones associated with the replication 
fork 5,6. Under certain circumstances, replication impediments can lead to 
dysregulation of gene expression due to interruption of the recycling of 
parental histones 7-10. The ability to induce this phenomenon at discrete loci 
could be used to reprogram the transcriptional activity of certain genes. 
 
We have previously described a manifestation of this phenomenon in the BU-
1 locus of chicken DT40 cells 9. We have shown that instability of BU-1 is 
induced in a replication-dependent manner by a DNA sequence that can form 
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a replication-blocking G-quadruplex (G4) secondary structure. G4s form in G-
rich DNA as a consequence of the ability of guanine to form 
thermodynamically stable Hoogsteen base-paired quartets 11. These 
structures present a significant impediment to DNA replication and are 
becoming appreciated as an important genomic feature 12-14. DT40 cells 
lacking key enzymes involved in G4 replication, for example the FANCJ 
helicase, REV1 DNA polymerase or PrimPol DNA primase/polymerase 8,9,15, 
or that are subjected to global replication stressors, such as hydroxyurea or 
aphidicolin 10, exhibit stochastic loss of normal BU-1 expression. We proposed 
that this results from localised uncoupling of the replicative helicase and 
polymerase on the leading strand resulting in correct DNA replication but a 
high frequency of loss of parental histone modifications. The resulting altered 
pattern of chromatin modifications is epigenetically inherited across cellular 
divisions and results in a permanent alteration in gene expression (Fig. 1a) 9. 
 
Here we report the use of small molecules to induce heritable epigenetic 
changes in the BU-1 locus of DT40 cells through stabilisation of a single G4 
motif. We exploit this phenomenon to design a sensitive assay to screen for 
small molecules capable of inducing G4-dependent transcriptional 
reprogramming of the BU-1 locus and hence of specific and effective in vivo 
G4 stabilisation. We identified several small molecules that are able to induce 
loss of BU-1 expression in a G4-dependent manner without significant 
perturbation of growth. We show that our lead compound, PDC12, induces the 
stochastic formation of variants with reduced Bu-1 expression in a dose-
dependent manner over a wide concentration range. PDC12 triggers 
inactivation of the locus in two steps, first the loss of promoter H3K4me3, 
which subsequently leads to histone H3K9 and DNA cytosine methylation and 
complete shutdown of expression. Further, these changes persist after 
removal of the compound, showing that they are epigenetically heritable. This 
work demonstrates that stabilisation of DNA secondary structures by small 
molecules can be harnessed for high yield reprogramming of gene expression 
and suggests a potential new approach to epigenetic therapy. 




Expression of the BU-1 locus in wild type DT40 cells can be impaired by the 
use of G4-ligands.  
As previously reported 9, the stochastic loss of BU-1 expression under 
conditions of replication stress is dependent on a G4-forming sequence within 
the second intron of the gene (at 3.5 kb from the transcription start site (TSS) 
and subsequently referred to as the ‘+3.5 G4’). This G4 blocks leading strand 
replication of forks heading towards the TSS from the 3' end of the locus (Fig. 
1a). This switching of expression of the locus away from the wild type Bu-1high 
state, which results from a reduction in transcription, can be readily monitored 
in individual cells using an antibody specific for surface Bu-1 protein coupled 
with flow cytometry 8,9 (Fig. 1b).  
 
We first assessed the ability of known G-quadruplex ligands such as N-methyl 
mesoporphyrin IX (NMM) 16, PhenDC3 17 and Pyridostatin (PDS)  18 to induce 
Bu-1 loss variants (i.e. expression variants that have lost the wild type (WT) 
Bu-1high state; Fig. 1b) in WT DT40 19. Having determined the maximum dose 
of each compound that DT40 cells tolerate without any impact on doubling 
time, we set up a fluctuation analysis 9,20 for the emergence of Bu-1 
expression variants in the presence of each ligand. A fluctuation analysis 
allows an estimate of the probability of a stochastic event per cell division 
when it is only possible to assess the prevalence of the event in a population. 
This is achieved by taking multiple parallel cultures through a defined number 
of cell divisions and examining the prevalence of the event, in this case the 
fraction of Bu-1 loss variants, at the end time point. Therefore, for each 
condition we started with 12 replicates of 5 cells per well in a 96 well plate and 
expanded these cells for 7 days, corresponding to approximately 14 cell 
divisions. In parallel with monitoring the proportion of Bu-1 loss variants in 
each well by flow cytometry, we recorded the final number of cells and 
consequently estimated the doubling time. As a control, we also treated cells 
in which the +3.5kb G4 had been deleted on both alleles 9, BU-1∆G4 (Fig. 1c). 
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We found that all three compounds generated Bu-1 loss variants in WT but 
not in BU-1∆G4 cells, demonstrating that the stabilisation of this specific G4 is 
sufficient to induce stochastic loss of Bu-1 expression. PDS was then used to 
explore whether the fraction of cells exhibiting reduced BU-1 expression is 
related to dose. PDS was found to produce a linear dose-response for the 
frequency of Bu-1 loss variants at 7 days. However, it was not possible to 
generate a population with more than 50% Bu-1 expression variants due to 
acute toxicity of the compound at ≥ 5 µM (Supplementary Fig. 1). 
  
In vivo screening for small molecules that cause G4-dependent epigenetic 
instability.  
A sensitive assay that provides a read out for the explicit interaction of 
compounds with G4s in the genome of living cells enables the discovery of G4 
targeted ligands with defined in vivo activity. Encouraged by the results 
presented above, we decided to employ BU-1 as a reporter locus to identify 
molecules capable of inducing G4-mediated transcriptional reprogramming 
and that exhibited an improved biological activity and therapeutic index. We 
first assessed the physiochemical properties of PDS, and other quadruplex 
ligands, using the “Lipinski rule of five” criteria (Fig. 1d) 21 that helps estimate 
a molecule’s ability to be absorbed by passive diffusion through cell 
membranes 22. We then postulated that decreasing the molecular weight, 
polar surface area, the number of hydrogen bond acceptors/donors and 
hydrophobicity of PDS should lead to small molecules combining the efficacy 
of PDS as a G-quadruplex ligand with increased bioavailability and wider 
therapeutic index (Supplementary Table 1). It is known that for small 
molecules a balance between cell permeability and potency must be struck, 
as low molecular weight and neutral compounds are generally more 
permeable whereas higher molecular weight compounds are generally more 
potent 23. Therefore, we designed and synthesised small molecules based on 
a pyridine-2,6-dicarboxamide (PDC) scaffold to generate a library of 32 low 
molecular weight, neutral compounds (Fig. 1e and Supplementary Methods). 
It is noteworthy that pyridine dicarboxamides of the same structural type as 
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the PDC derivatives have been previously described as potential inhibitors of 
the action of telomerase via targeting the telomeric DNA G-quadruplex 24. 
Each PDC compound was screened for its effect on cell doubling time and the 
stability of BU-1 expression in a fluctuation analysis for loss of the Bu-1high 
state using WT DT40 cells. Each compound was assessed at two doses (5 
µM and 10 µM), in triplicate and starting from 5 cells, as described above. 
After seven days of culture, the final viable cell number and percentage of Bu-
1 expression variants was monitored by flow cytometry. The median 
percentage of Bu-1 loss variants in each culture is reported as a function of 
the estimated number of cell divisions (Fig. 2a). Compounds falling into the 
lower left quadrant (highlighted by the red area) are those that significantly 
inhibit growth while compounds in the lower right quadrant did not affect 
growth, but had no effect on Bu-1 expression. Ligands of interest (highlighted 
by the green area) appear in the upper right quadrant, as these molecules 
induced loss of Bu-1 expression without affecting cellular growth. At 5 µM, the 
compound that most potently induced loss of the Bu-1high expression state 
was PDS. However, at 10 µM, PDS became toxic, but several of the PDC 
derivatives (PDC12, 14, 22, 23, 25 and 40) were able to induce significant 
numbers of Bu-1 loss variants without appreciable toxicity (Fig. 2a).   
 
In a second step, we biophysically assessed the ability of each of these 
compounds to stabilise the Bu-1 G4 in vitro using Circular Dichroism (CD) 
spectroscopy-based thermal denaturation assays (to avoid fluorescence or 
UV-based experiments with which the small molecules themselves may 
interfere). Melting curves, followed at 263 nm, were recorded in the absence 
and presence of 5 equivalents (10 µM) of each of the small molecules and the 
stabilisation potency was extracted as the increase in melting temperatures 
(∆T1/2, Supplementary Table 1). Taking into consideration the quantitative 
estimate of drug-likeness (QED) 22, (Supplementary Table 1), we identified 
the different compounds that displayed in vitro G4 stabilising properties and 
suitable theoretical physicochemical properties (Fig. 2b). The G4-stabilising 
molecules with weighted QED values > 0.5 (highlighted by the green area in 
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Fig. 2b) represented the interesting hits from this biophysical screen. A plot 
showing the median number of Bu-1 loss variants generated in seven days as 
a function of ∆T1/2 (Fig. 2c) highlighted the six compounds, PDC12, 14, 22, 23, 
25 and 40, as potential candidates for quadruplex-dependent reprogramming 
of BU-1 expression. We confirmed, using an alternative FRET-melting assay, 
the ability of each of the molecule to stabilise several unrelated quadruplex 
motifs in vitro alongside their ability to trigger loss of Bu-1 expression 
(Supplementary Fig. 2). Fig. 2d reports the structures of the four most potent 
molecules. It is noteworthy that these molecules all display improved 
physicochemical properties as compared as the parent molecule PDS. To 
confirm that these compounds acted directly on the +3.5 G4 motif, the 
fluctuation analysis was repeated by challenging the BU-1∆G4 cells in parallel 
with wild type ones (Fig. 2e) with the four best small molecules. None of these 
ligands produced any significant effect on the expression stability of BU-1 
when the +3.5 G4 motif was deleted. This demonstrated that the induction of 
BU-1 instability by these compounds was completely dependent on the 
presence of the G4 motif. Due to its higher apparent potency, PDC12 was 
selected for further investigation of BU-1 reprogramming. 
 
PDC12-mediated BU-1 reprogramming is dose, G4 and replication dependent.  
We next asked whether PDC12 was able to induce more complete 
reprogramming of BU-1 expression than PDS, which is limited by toxicity. A 
dose-response fluctuation analysis using the previous experimental design 
was performed and PDC12 was found to be active over a range of up to 80 
µM without detectable toxicity (Fig. 3a), with a dose of 40 µM causing > 75% 
of all cells to lose wild type levels of Bu-1 expression, while BU-1∆G4 exhibited 
no significant increase in the formation of Bu-1 loss variants above the 
background of the flow cytometry assay.	  We then used a FRET-melting assay 
to further assess the G4-binding properties and selectivity of PDC12 in vitro 
(Fig. 3b). Micromolar doses of PDC12 were found to stabilise the BU-1 G4 
motif. We could demonstrate a significant thermal stabilisation (up to 35°C at 
40 µM, Fig. 3c) of the +3.5 G4, and this was not affected by the presence of 
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competing genomic DNA, demonstrating specificity of the compound for the 
BU-1 G4 (Fig. 3d). To further elucidate the mechanism by which PDC12 
reprograms BU-1, we employed a Monte-Carlo simulation 9 to assess the 
correlation between the generation of Bu-1 loss variants and cell division. The 
simulation 9 is based on modelling the probability for each cell to irreversibly 
lose expression of wild type levels of Bu-1 at each cell cycle (Fig. 3e).  
Running the simulation with varying probabilities of loss of BU-1 expression 
per cell cycle allows the generation of a function that can be compared with 
the experimental data and used to compute the probabilities of loss for each 
concentration. The model was found to accurately recapitulate the kinetics 
with which Bu-1 loss variants are generated (R2 = 0.9989, Spearman 
correlation) (Fig. 3f) and allows an estimation of the per division probability of 
this event. For example, according to the model, the probability of conversion 
at 40 µM PDC12 is more than 7% per cell cycle. Interestingly, the probability 
of loss strongly correlates with the dose of the compound (R2 = 0.9436, 
Spearman correlation, Fig. 3f) supporting the idea that PDC12-induced loss of 
Bu-1 expression requires cell division. Together, these observations are 
consistent with the PDC12-mediated reprogramming of BU-1 locus being 
dependent on the small molecule dose, the BU-1 +3.5 G4 motif and DNA 
replication.  
 
PDC12 induces repression of Bu-1 expression in two steps.  
To explore underlying mechanisms for the loss of Bu-1 expression in 
response to increasing PDC12 doses, five cells were expanded for seven 
days in the presence of 20 µM or 40 µM PDC12 or DMSO, then four replicate 
samples were pooled and expanded for a further seven days to allow recovery 
of sufficient material for expression and ChIP analysis. 
 
We first looked at BU-1 transcript levels. Exposure to PDC12 resulted in a 
dose-dependent reduction in BU-1 mRNA (Fig. 4a). Exposure of cells to some 
G4 ligands has been associated with the induction of DNA damage and the 
phosphorylation of H2Ax, a mechanism that has been linked to an acute 
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reduction in gene expression 25. We therefore asked whether PDC12 induced 
a measurable DNA damage response by monitoring the induction of histone 
H2Ax and CHK1 S345 phosphorylation. It did not, even when cells were 
exposed to the highest dose (80 µM) used in these studies for two weeks 
(Supplementary Fig. 3). Further, the compound did not induce any change in 
the cell cycle (Supplementary Fig. 4). We were also unable to detect 
mutations of the +3.5 G4 motif suggesting that the formation of Bu-1 loss 
variants was not explained by mutation of the BU-1 locus around the G4 motif 
(Supplementary Fig. 5). Next, using chromatin immunoprecipitation, we 
monitored levels of H3K4me3, a histone modification associated with active 
transcription, around the TSS of BU-1. H3K4me3 was significantly reduced in 
the populations treated with both 20 µM and 40 µM PDC12 relative to the 
control (Fig. 4b). We also found a concomitant gain of H3K9me3 
(Supplementary Fig. 6), consistent with our previous studies on mutants 
defective in G4 unwinding 8,9. However, there was no difference between the 
20 µM and 40 µM conditions (Fig. 4b and Supplementary Fig. 6). This 
suggests that the additional repression of transcript production in cells treated 
with the higher dose of PDC12 may result from an additional mechanism. 
Examination of the distribution of expression of Bu-1 in the cells treated with 
20 µM and 40 µM revealed that the latter exhibited an additional population 
with practically no expression of Bu-1 (Fig. 4c & d). This presence of a 'third', 
Bu-1low, state was reminiscent of the pattern of BU-1 expression in cells 
lacking the primase-polymerase, PrimPol 15. In this previous study, we 
showed that primpol Bu-1low cells had acquired DNA methylation at BU-1 in 
addition to the loss of H3K4me3 seen in the Bu-1medium population.  
 
We therefore examined the way in which PDC12 induced the Bu-1medium and 
Bu-1low states in more detail. The appearance of Bu-1medium and Bu-1low 
populations is dependent on both the dose of drug and number of cell 
divisions (Fig. 5a). Thus, using 20 µM PDC12, a ratio of Bu-1medium: Bu-1high of 
3 : 7 was achieved in 15 days. The same ratio was reached with 40 µM and 
80 µM doses in just 10 and less than 8 days respectively. Consistent with our 
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previous observations in PrimPol-deficient cells 15, the Bu-1low state required 
the prior establishment of a Bu-1medium population. The appearance of Bu-1low 
cells thus lagged behind the Bu-1medium population and they were only 
observed in significant numbers after 13 days in cells treated with 40 µM and 
80 µM of the compound. Indeed, after this time, exposure to 80 µM PDC12 
gave rise to an almost completely Bu-1low population.  
 
The ability to control the formation of Bu-1 loss variants with PDC12 allowed 
us to assess the reversibility of each transition and the requirement for G4 
stabilisation. We therefore selected a population that had been treated with 40 
µM PDC12 for 16 days and that exhibited all three states (Fig. 5b). We sorted 
individual Bu-1high, Bu-1medium or Bu-1low cells into separate wells and 
expanded them for three weeks in the absence of PDC12. Bu-1 expression 
was then reassessed by flow cytometry (Fig. 5b). As expected, Bu-1high 
clones no longer generated Bu-1 loss variants in the absence of the 
compound. However, the majority of Bu-1medium clones (22 out of 24) 
spontaneously became Bu-1low, while none reverted to being Bu-1high. Bu-1low 
cells remained in this state. 
 
To further characterise the cause of the irreversible Bu-1low state, we analysed 
CpG DNA methylation around the BU-1 locus. Genomic DNA of clones 
representing the three states was then extracted and subjected to bisulfite 
conversion. Seven regions around the BU-1 TSS were PCR amplified and 
sequenced in order to interrogate their CpG methylation status (Fig. 5c). 
While both Bu-1high and Bu-1medium cells had a very low level of CpG 
methylation of the BU-1 locus, Bu-1low cells exhibited a significant increase, 
suggesting formation of heterochromatin (Fig. 5d & e). 
 
Together, our observations demonstrate that PDC12 exposure leads to the 
sustained methylation of the BU-1 promoter in a dose-dependent manner. 
Further, this expression state persists following removal of the G4 ligand 
demonstrating that the ligand has triggered an epigenetically heritable change 
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in the expression state of the gene.  Mechanistically, we show that this takes 
place in two steps. The first results from loss of H3K4me3 and is consistent 
with our previous model of epigenetic instability induced by localised G4-
dependent replication arrest 8,9. This loss of H3K4me3 appears then to render 
the locus vulnerable to DNA methylation and total shut down of expression of 
the gene, but this second phase takes place without a requirement for the 




Here we report a robust and sensitive approach to evaluate small molecules 
for their ability to interact with genomic G4s. Using the extensively 
characterized BU-1 locus as reporter 8-10,15, we describe a sensitive in vivo 
screening platform that links a genomic G4 motif with a robust phenotypic 
readout in the generation of Bu-1 loss variants. By combining this in vivo 
assay with biochemical and computational approaches we have identified G4 
interacting compounds with well-defined cellular intervention properties, while 
retaining low toxicity.   
 
We show that the per division probability of a cell losing full expression of Bu-
1 can be controlled by the dose of the G4 ligand used, suggesting that this 
assay monitors the in vivo potency of a specific ligand – G4 pair. It is 
noteworthy that the example of the +3.5 BU-1 G4 reveals that the ability of a 
compound to bind a G4 in vitro does not necessarily translate into in vivo 
potency. While there is a general trend linking the in vitro ability of the top hit 
compounds to stabilise G4s and their in vivo ability to induce G4 motif-
dependent expression instability at BU-1 (Supplementary Fig. 2g), the 
correlation is not a strict one. This likely reflects the complexity of G4 
formation and stabilisation in vivo and highlights the potential limitations of in 
vitro biophysical measurements. Since the cellular assay, which we describe 
here, is easily scalable it should be suitable for automation and allow the 
screening of larger chemical libraries. Coupled with the genetic tractability of 
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DT40 cells this approach could be expanded to the study of other G4 or DNA 
structural sequences/motifs, inserted in place of the +3.5 BU-1 G4 allowing a 
more detailed understanding of the interaction of specific ligands with G4 
targets in vivo. 
 
While the use of a G4 ligand to induce gene expression changes is inevitably 
accompanied by the possibility that the observed effects are indirect, for 
example through inhibition of a G4-processing enzyme, the observation that 
chemically diverse compounds destabilise BU-1 expression in a manner 
requiring the +3.5 G4 motif (Fig. 1c and 2e) provides some confidence that 
they are indeed acting directly on the structure in vivo. There are a number of 
potential mechanisms by which G4 stabilisation can affect gene expression. 
Early studies by Hurley and colleagues demonstrated that the stabilisation of 
a G4 within the NHE III1 (nuclease hypersensitivity element) in the promoter of 
the c-Myc oncogene resulted in repression of transcription by preventing 
binding of key transcription factors 26, establishing a paradigm for direct 
transcriptional regulation by G4 stabilisation 27. G4 stabilisation has also been 
proposed to influence transcription indirectly by causing DNA damage, 
especially double strand breaks 25. The repair of double strand breaks in 
active genes results in transient transcriptional repression through 
heterochromatin formation 28,29. However, in neither case has the G4 
stabilising compound has been shown to exert an epigenetically heritable 
effect on gene expression that persists even after removal of the compound. 
The data we present here shows that heritable and durable chromatin 
remodelling can be achieved by exploiting the ability of stabilised G4s to 
locally interrupt the propagation of epigenetic information through S phase. 
 
We have taken advantage of the broad usable concentration range of PDC12 
to shed further light on the step-wise mechanism by which the BU-1 locus is 
reprogrammed. In a first step, stabilisation of the BU-1 G4 results in the 
structure becoming a more significant impediment to replication. The 
observation that G4 ligands induce instability of expression of the BU-1 locus 
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suggests that G4s actually form frequently during DNA replication, but are 
usually rapidly resolved. This may explain why some G4 motifs are associated 
with replication slow zones, for example the G4 within the chicken ρ-globin 
gene 30. We propose that the additional delay to replication imposed by the 
stabilisation of the structure leads to significant uncoupling of DNA synthesis 
and histone recycling leading to loss of the H3K4me3 normally found around 
the TSS of the gene, similar to cases where replication of the G4 is delayed 8,9.  
The ability to control G4 stabilisation by removal of the ligand revealed that 
the subsequent appearance of DNA methylation, and further repression of 
expression, does not require the G4 to remain a replication impediment. The 
mechanism by which this DNA methylation is installed remains to be 
investigated. However, it may simply be a consequence of the loss of 
H3K4me3, which inhibits DNA methylation 31,32. H3K4me3 interferes with the 
activation of the de novo DNA methyltransferase DNMT3A by preventing the 
binding of the ADD domain of the enzyme to H3K4. Inability to bind H3K4 
prevents the conformational change necessary to release the auto inhibition of 
the catalytic activity of the enzyme by the ADD domain 33. Thus, our data is 
consistent with the idea that replication-dependent maintenance of H3K4me3 
at gene promoters not only represents a mechanism to facilitate stable, high 
level transcription but also prevents aberrant silencing by DNA methylation. 
 
In summary, we demonstrate the principle of reprogramming the 
epigenetically determined transcriptional state of a locus through G4 
stabilisation. Our observations suggest that targeting secondary structures in 
DNA to trigger replication-dependent reprogramming of key genes could 
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Methods 
 
DT40 cell culture and mutants. DT40 cells were cultured as previously 
described 34. Manipulation of the BU-1 locus, including the derivation of the 
BU-1∆+3.5G4 line has been described previously 9,10.  
 
G-quadruplex ligands. The small molecules Pyridostatin (PDS) and 
PhenDC3 were synthesised as previously reported 17,18. N-Methyl 
Mesoporphyrin IX (NMM) was purchased from Frontier Scientific (Catalogue 
No:  NMM580). Detailed procedures for the synthesis of pyridine-2,6-
dicarboxamide (PDC) derivatives and their characterization are provided in 
the Supplementary Methods. Physicochemical properties were predicted 
using ChemAxon Marvin (http://www.chemaxon.com). 
 
Surface Bu-1 staining and analysis. Gene expression variation of the BU-1 
locus in WT DT40 cells is reported for the BU-1A allele only, using a Bu-1A 
antibody (Santa Cruz  70447)  coupled with Phycoerythrin (PE). As previously 
described,9 DT40 is an F1 hybrid expressing both Bu-1A and Bu-1B. All flow 
cytometry was carried using BD™ LSR II flow cytometer and analysed with 
FlowJoTm. Bu-1A expression has been gated using in Y-axis side scatter 
(SSC) and in X-axis Phycoerythrin (PE) fluorescence. Data was exported and 
further computation and plots performed using home-made R 35  scripts using 
the Beeswarm package 36. p-values were assessed by Fisher’s tests of 5 
windows (corresponding to bins of 20%) as previously described 9.  
 
Chromatin Immunoprecipitation (ChIP) and RT-qPCR. ChIP was 
performed as previously described 9. Total mRNA was extracted with TRIzolTM 
following the manufacturer's instructions. mRNA was converted into cDNA 
with the QuantiTect Reverse Transcription Kit (Qiagen cat nº 205311). 
Quantitative PCR was performed on a ViiA™ 7 Real-Time PCR System 
(ThermoFisher Scientific) using Power SYBR® Green PCR Master Mix 
(ThermoFisher cat nº 4367659). Ct thresholds were determined with the 
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ViiA™ 7 software and the results analysed with custom R 35 scripts. Primers 
used are given in Supplementary Methods. For ChIP, quantitation was 
computed using the formula 𝑬^(𝑪𝒕𝑰𝒏𝒑𝒖𝒕!𝑪𝒕𝒔𝒂𝒎𝒑𝒍𝒆)
𝑬^(𝑪𝒕𝑰𝒏𝒑𝒖𝒕!𝑪𝒕𝑯𝟑)
. Quantitation of mRNA levels 
were computed using the formula E^(Ct(BU-1) – Ct(Actin)). E corresponds to 
primer efficiencies (Supplementary Methods). 
 
Circular dichroism (CD) denaturation studies. CD experiments were 
conducted on a Chirascan Plus spectropolarimeter. Oligonucleotide solutions 
were prepared at a final concentration of 2 μM in 10 mM lithium cacodylate 
(pH 7.2) containing 1 mM of EDTA and 100 mM of KCl. The samples were 
annealed by heating at 95 °C for 10 min and slowly cooled to 20 °C. The small 
molecules were directly added to the oligonucleotide solutions from 10 mM 
DMSO stock solutions for a final concentration of 10 μM. Each sample was 
transferred to a quartz cuvette with 1 cm path length, covered with a layer of 
mineral oil, placed in the spectrophotometer and equilibrated at 5 °C for 10 
min. Samples were then heated to 95 °C at a rate of 1 °C/min, with data 
collection every 1 °C. The CD signal at 263 nm was monitored and melting 
temperature (T1/2) values were extracted as the half-maximum increase in 
ellipticities. 
 
Förster resonance energy transfer (FRET) melting experiments. 
Fluorescence experiments were conducted on a Varian Cary Eclipse 
spectrophotometer. A dual-labelled G4-BU-1 oligonucleotide, referred to as Fl-
G4-BU-1, was used. The donor fluorophore was 6-carboxyfluorescein (FAM), 
and the acceptor fluorophore was 6-carboxytetramethylrhodamine (TAMRA). 
Oligonucleotide solutions were prepared at a final concentration of 200 nM in 
10 mM lithium cacodylate (pH 7.2) containing 1 mM of EDTA and 100 mM of 
KCl. The samples were annealed by heating at 95 °C for 10 min and slowly 
cooled to 20 °C. PDC12 was directly added to the oligonucleotide solutions 
from a 10 mM DMSO stock solution. For competition experiments with 
genomic DNA, human placental DNA (Sigma) was directly added from a 1 
mg.mL-1 solution. Each sample was transferred to a quartz cuvette with 1 cm 
	   16	  
path length, covered with a layer of mineral oil, placed in the 
spectrophotometer and equilibrated at 5 °C for 10 min. Samples were then 
heated to 95 °C at a rate of 1 °C/min, with data collection every 1 °C. FRET 
signals were monitored using an excitation wavelength of 483 nm and a 
detection wavelength of 533 nm. Melting temperature (T1/2) values were 
extracted as the half-maximum decrease in fluorescence. 
 
Bisulfite sequencing. Bisulfite conversion was achieved using the 
TrueMethyl Seq kit (Cambridge Epigenetix), following the manufacturer’s 
instructions, starting with 1 μg of genomic DNA. After oxidation and bisulfite 
treatment, regions of interest from the BU-1 locus were amplified by PCR, 
using the VeraSeq Ultra DNA polymerase (Enzymatics) and bisulfite primers 
(Supplementary Methods). The amplicons were then blunt ended 
(NEBNext® End Repair Module) and dA-tailed (NEBNext® dA-Tailing Module), 
before ligation of Illumina adapters. Libraries were quantified using the KAPA 
Library Quantification Kits (Kapa Biosystems). Sequencing was performed on 
an Illumina NextSeq 500 with paired-end 300 cycle reads. Counts of 
converted and unconverted cytosine, i.e the methylation status, in the BU-1 
locus were obtained after Trimming reads by seqtk (H.	   Li,	  
https://github.com/lh3/seqtk/),	   alignment using Bismark 37 and Bowtie2 38. 
Data extracted from Bismark were further analysed and the Fig. generated 
with a  home-made R 35 script. 
 
Data Availability Statement 
All the data presented and analysed in this study are either included in this 




GG and PM designed, performed and analysed the experiments. BR analysed 
the impact of PDC12 on the DNA damage response. BCC and PM 
synthesised the G4 ligand library. AM performed the first screen of the library 
	   17	  
with GG. GG, PM & JES wrote the manuscript with contributions from all 
authors. JES and SB supervised the project.  
 
Acknowledgments 
The authors would like to thank Milena Stankovic for her help in genotyping 
PCR across BU-1 G4 and with the ChIP experiment. Maria Daly, Fan Zhang 
and Veronika Romashova in the LMB flow cytometry facility for cell sorting, 
Jake Grimmett and Toby Darling in LMB scientific computing for their help in 
massive sequencing analysis and Chris Lowe for proofreading the manuscript. 
Work in the Sale group is supported by a central grant to the LMB by the MRC 
(U105178808). SB is a Wellcome Trust Senior Investigator (grant no. 
099232/z/12/z). The Balasubramanian group is supported by a European 
Research Council Advanced Grant (no. 339778) and receives core funding 
(C14303/A17197) and programme funding (C9681/A18618) from Cancer 
Research UK.  
 
Correspondence and Materials  
Correspondence and requests for materials should be addressed to Julian 
Sale (jes@mrc-lmb.cam.ac.uk) and Shankar Balasubramanian 
(sb10031@cam.ac.uk). 
 
Conflict of interest 
The authors declare that they have no conflict of interest 
 
 
Figure Legends:    
 
Fig. 1 | DT40 BU-1 gene expression is a sensitive screen for the in vivo 
activity of G4 ligands (a) Working model for replication-dependent loss of 
localised epigenetic marks 4,7,9. When the leading strand of a replication fork 
stalls at a G4 motif, histone recycling may be interrupted by the formation of a 
post-replicative gap resulting in loss of the parental epigenetic state for up to c. 
4 kb downstream the G4 site. (b) Bu-1 loss variants. Flow cytometry for Bu-1 
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expression in WT DT40 cells treated with PDS showing gating for the wild 
type Bu-1high state (green region) and for Bu-1 expression variants (red 
region), which are quantitated as ‘percentage of Bu-1 loss’ in subsequent 
plots. (c) Induction of G4-dependent instability of Bu-1 expression with G4 
ligands. WT or Bu-1∆G4 DT40 were treated with either 5 µM PhenDC3, 2 µM 
NMM or 4 µM PDS starting from 5 cells for 7 days and then BU-1 level was 
monitored by flow cytometry. Red bar = median loss; whiskers = interquartile 
range; p-values for the comparison of Bu-1 loss distributions were calculated 
with Fisher’s tests of 5 windows spanning 20% BU-1 loss each, ***: p < 0.001, 
n.s: p = 1. (d) Radar chart reporting the physiochemical properties of NMM 
(purple), PhenDC3 (blue) and PDS (red). The green shaded area indicates the 
optimum range for each feature. Abbreviations (with optimum range) nOHNH 
= number of hydrogen bond donors (≤ 5); n ON = number of hydrogen bond 
acceptors (≤ 10); Mw = molecular mass (≤ 500 Da); PSA = polar surface area 
(80-140 Å2); clogD = partition coefficient (≤ 5) (e) Scheme for the creation of 
derivatives of PDS based on a pyridine-2,6-dicarboxamide scaffold. Details of 
Ar1 and Ar2 and the final compound library are given in Supplementary 
Methods. 
 
Fig. 2 | In vivo screen for new G4 quadruplex ligands. (a) Effect of the 
PDC-derivatives on induction of Bu-1 loss variants and on cell proliferation 
after seven days. The plot shows the result of three independent repeats. 
Data presented on the plot were generated using 10 µM of the PDC 
derivatives and 5 µM of NMM, PhenDC3 or PDS. The green shaded area 
indicates compounds that were able to induced significant numbers of Bu-1 
expression variants without significantly reducing cell growth. (b) Plot of 
induced thermal stabilisation of the BU-1 +3.5 G4 5’-
d(GGGCTGGGTGGGTGCTGTCAAGGGCTGGG) as a function of the 
weighted quantitative estimate of drug likeness (QEDwmo) 22. Thermal 
stabilisation was monitored using CD spectroscopy of the BU-1 +3.5 G4 (2 
µM) with 5 equivalents of the small molecule under test. (c) Plot of percentage 
of Bu-1 loss variants after exposure to each compound for 7 days plotted as a 
	   19	  
function of the induced thermal stabilisation of the +3.5 G4 motif. Horizontal 
and vertical bars, in panels a and c, represent standard errors among three 
repeats for the number of cell divisions and Bu-1 loss respectively. (d) 
Structure and physicochemical properties of the hits PDC12, 14, 22 and 40. 
(e) Induction of Bu-1 loss variants by the top four compounds requires the 
presence of the Bu-1 +3.5 G4. Repeat of the fluctuation analysis experiments 
shown in (a) for 10 µM over 7 days of PDC12, 14, 22 and 40 with DMSO as 
control on both WT and the Bu-1∆G4 DT40 control. Bars = median loss; 
whiskers = interquartile range; p-values for the comparison of Bu-1 loss 
distributions were calculated with Fisher’s tests of 5 windows corresponding to 
20% BU-1 loss, ns: non-significant, ***: p < 0.001, n.s: p = 1. 
 
Fig. 3 | G4- and PDC12-dependent induction of Bu-1 loss variants. (a) 
Generation of Bu-1 loss variants as a function of PDC12 dose assessed by 
fluctuation analysis. Main graph: Each bar represents the median percentage 
of Bu-1 loss variants after 7 days in parallel cultures started from 5 Bu-1 
positive cells (WT + PDC12 n= 24; WT + DMSO n = 12; Bu-1∆G4 + PDC12 n = 
12). Whiskers = interquartile range. Red: wild type cells treated with PDC12; 
black: wild type cells treated with DMSO; blue: Bu-1∆G4 cells treated with 
PDC12. The top graph shows doubling time for each condition with mean and 
interquartile range. (b - d) PDC12 stabilizes the BU-1 +3.5 G4 in a 
concentration-dependent manner. (b) Thermal denaturation profiles of a dual-
labelled BU-1 +3.5 G4 (200 nM) with an increasing concentration of PDC12 
(from 0 to 80 µM, blue to red curves). The BU-1 +3.5 G4 was labelled with 6-
FAM and TAMRA at its 5’ and 3’ ends (excitation at 494 nm and emission at 
580 nm). (c) Stabilisation induced by PDC12 is reported as the concentration-
dependent increase of the melting temperature (T1/2) of the G4/PDC12 
complex. (d) PDC12 selectively stabilises the BU-1 +3.5 G4 as exemplified by 
a competition experiment with genomic DNA. PDC12 (10 µM) was incubated 
with a dual-labelled BU-1 +3.5 G4 (200 nM) and an increasing concentration 
of genomic DNA (from 0 to 400 µg.ml-1) and the melting temperatures of the 
G4/PDC12 complex were recorded as previously described. (e) Diagrammatic 
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representation of the Monte Carlo computational model for emergence of Bu-1 
loss variants dependent of cell divisions 9. (f) The upper graph shows a 
simulation of the generation of Bu-1 loss variants taking into account the 
experimental conditions used in this study (black squares and dotted red line) 
overlaid with the experimental data (black circles and solid blue line). The 
lower graph shows the correlation between probability of Bu-1 loss per 
division calculated using the Monte Carlo simulation and the results of the 
fluctuation analysis.  
 
Fig. 4 | PDC12 reprograms histone marks leading to reduced mRNA 
expression. (a) Quantification of Bu-1 transcript levels by RT-qPCR as a 
function of PDC12 at 20 and 40 µM. Bu-1 transcript levels are normalised to 
actin B. Error bars show standard error of three biological replicates (each 
with three technical replicates). p-values computed with the Wilcoxon two-
sided test, *: p < 0.05 and ***: p < 0.001. (b) ChIP for H3K4me3 around the 
BU-1 TSS normalised to total input and to total H3. Each point represents 
results from three biological replicates (each with three technical replicates) as 
previously described 9. ChIP for H3K9me3 and controls are shown in 
Supplementary Fig. 6. Bars represent standard error. p-values computed by 
the use of Wilcoxon two-sided test, ***: p < 0.001. (c) Representative flow 
cytometry scatter plot of WT DT40 cells treated with 40 µM of PDC12 for 14 
days highlighting the gating for cells expressing high, medium and low level of 
Bu-1. Under this condition, PDC12 induces a third, Bu-1low expression state, 
not observed at seven days (Fig. 1b). (d) Bu-1 expression of cells used for the 
ChIP and qPCR experiments show in (a) and (b). Grey plot shows a control 
mix of WT Bu-1 positive DT40 and DT40 in which the BU-1 locus has been 
genetically disrupted. Triplicates have been performed for each condition 
(highlighted by different colours). 
 
Fig. 5 | PDC12 induces irreversible loss of Bu-1 expression and 
subsequently CpG methylation. (a) Bu-1 expression was found to depend 
on the duration and dose of PDC12 exposure. The flow cytometry profiles 
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report three independent biological replicates of the change in Bu-1 
expression after the indicated number of days (highlighted by different 
colours) and exposure to either 20, 40 or 80 µM PDC12. Grey plots show a 
control mix of WT Bu-1 positive DT40 and DT40 in which the BU-1 locus has 
been genetically disrupted. (b) The Bu-1high to Bu-1medium transition depends 
on PDC12, while the Bu-1medium to Bu-1low transition is spontaneous. Cells 
representative of a given expression state, after fourteen days in 40 µM 
PDC12, were sorted by FACS as depicted on the left hand-side. After three 
weeks in compound-free medium, several individual clones of each population, 
Bu-1high (light blue), Bu-1medium (dark blue) and Bu-1low (purple), were analysed 
by flow cytometry. (c - e) The irreversibility of the Bu-1low expression state can 
be explained by the DNA methylation of the BU-1 locus. (c) DNA methylation 
around the promoter and TSS of Bu-1low, Bu-1medium and Bu-1high populations. 
(d) Quantification of the percentage of methylation of the BU-1 locus. Black 
bar = median; whiskers = interquartile range. (e) Quantification of the 
percentage of methylated CpGs. p-values in (d) and (e) were computed by the 
use of Wilcoxon two-sided test, ns: non-significant, ***: p < 0.001. 
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